Dengue vaccines approach the finish line.

@article{Edelman2007DengueVA,
  title={Dengue vaccines approach the finish line.},
  author={Robert R. Edelman},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2007},
  volume={45 Suppl 1},
  pages={
          S56-60
        }
}
  • R. Edelman
  • Published 15 July 2007
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
The spread of dengue virus (DV) via its Aedes mosquito vector throughout most of the tropics has led to a worldwide resurgence of epidemic dengue, including dengue hemorrhagic fever. For the first time in 60 years, the pipeline of dengue vaccines looks promising. Strains of each of the 4 DV serotypes, attenuated by passage in tissue culture or by recombinant DNA technology, have been formulated into tetravalent vaccines and have entered successful phase 1 and 2 clinical trials in the United… 
View on PubMed
academic.oup.com
95 Citations
Highly Influential Citations
4
Background Citations
44
Methods Citations
3

95 Citations

Citation Type

Citation Type

Progress towards a dengue vaccine.
Advancements in developing an effective and preventive dengue vaccine
TLDR
Chimeric yellow fever virus-tetravalent dengue vaccine (CYD-TDV) is the first licensed vaccine developed by Sanofi Pasteur in December 2015, but this vaccine is not fully effective against different d Dengue virus serotypes.
Review of dengue virus and the development of a vaccine.
Medical Biotechnology Dengue: Possible strategies for molecular vaccine production
TLDR
Plasmid vectors express single open reading frame, which carries domain III of E protein of all dengue serotypes which are separated from each other by proteolytic cleavage sites, which is the ultimate solution for preventing all denge virus serotypes.
Newer Vaccines against Mosquito-borne Diseases
Mosquitos are responsible for a number of protozoal and viral diseases. Malaria, dengue, Japanese encephalitis (JE) and chikungunya epidemics occur commonly all over the world, leading to marked…
A Mini-review of Dengue Vaccine Development
TLDR
There is an urgent need to develop a safe and effective vaccine that induces protective immune response to all the four serotypes overcoming antibody dependent enhancement.
Overview of dengue viruses and their relations.
TLDR
This review summarizes current basic knowledge of dengue virus infection, based on clinical and laboratory studies, and should be useful for developing disease control programs and further research.
Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
Estado actual de las vacunas contra el Dengue: perspectivas
TLDR
It is expected to have available a dengue vaccine in the near future, that may complement the existing strategies of control disease, and some information on guidelines coordinated by the WHO to conduct clinical trials, and regulatory aspects to be considered for the future license of these d Dengue vaccines are included.
Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection
TLDR
VSV is a promising platform to test as a DENV vaccine and perhaps against others Flaviviridae, as VSV has been successfully used as vaccine vectors for several viruses to induce strong humoral and cellular immune responses.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.
  • B. Innis, K. Eckels
  • Medicine
    The American journal of tropical medicine and hygiene
  • 2003
TLDR
The preclinical and early clinical development of the WRAIR liveattenuated tetravalent DENV vaccine candidate is the subject of the following seven papers in this supplement.
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.
Live attenuated tetravalent dengue vaccine.
Pathogenesis of dengue: challenges to molecular biology.
TLDR
This work has identified a severe syndrome, dengue hemorrhagic fever/dengue shock syndrome, in Southeast Asian children, which recently has also been identified in children infected with the virus in Puerto Rico.
Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.
TLDR
Most volunteers experienced clinically moderate fever, headache, myalgia, eye pain or rash 7-11 days after injection, generally lasting three days or less, and Modest decreases in platelets and neutrophils were observed.
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
Microevolution and virulence of dengue viruses.
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
TLDR
Seven formulations met the serologic criteria required for an expanded trial, and three were sufficiently attenuated clinically to justify further testing and would be considered for an expand Phase II trial in the future.
The dengue viruses.
TLDR
Patients present with a severe febrile illness characterized by abnormalities of hemostasis and increased vascular permeability, which in some instances results in a hypovolemic shock.
Research on dengue during World War II.
  • A. Sabin
  • Medicine
    The American journal of tropical medicine and hygiene
  • 1952
TLDR
Dengue research was brought from the field into the laboratory and further progress has been made possible by work on experimental animals instead of on human volunteers, and a great deal more was learned about the basic properties of the dengue viruses.
...
1
2
3
4
...